

John Fling, MD  
Texas College of Osteopathic Medicine  
Pediatrics  
Email: John.Fling@unthsc.edu



## Area of Expertise

Dr. Fling is board certified in Allergy/Immunology and Pediatrics with over thirty years of experience caring for adults, children, and infants. His main focus is the care and management of individuals suffering from allergies and asthma. He uses evidence-based practice for the diagnoses and treatment strategies, along with patient input to create the optimal treatment plan. In addition to clinical practice, Dr. Fling has been involved as principal investigator in multiple research studies and has a special interest in the development of new vaccines. He is a member of American Academy of Allergy, Asthma, and Immunology, Tarrant County Medical Society, and a fellow of the American Academy of Pediatrics.

## Qualifications

BS in Biology, Southwest Texas State University  
MD, University of Texas Health Science Center at San Antonio

## Publications

### **Immunogenicity and safety of an MF59-adjuvanted quadrivalent seasonal influenza vaccine in young children at high risk of influenza-associated complications: A Phase III, Randomized, observer-blind, multicenter clinical trial**

Esposito, S., Fling, J., Chokephaibulkit, K., De Bruijn, M., Oberye, J., Zhang, B., Vossen, J., Heijnen, E. & Smolenov, I., 1 Aug 2020, In : Pediatric Infectious Disease Journal. 39, 8, p. E185-E191

### **Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study**

Klein, N. P., Abu-Elyazeed, R., Povey, M., Macias Parra, M., Diez-Domingo, J., Ahonen, A., Korhonen, T., Tinoco, J. C., Weiner, L., Marshall, G. S., Silas, P. E., Sarpong, K. O., Ramsey, K. P., Fling, J. A., Speicher, D., Campos, M., Munjal, I., Peltier, C., Vesikari, T., Baccarini, C. & 4 others, Caplanusi, A., Gillard, P., Carryn, S. & Henry, O., 30 Apr 2020, In : Journal of the Pediatric Infectious Diseases Society. 9, 2, p. 194-201 8 p.

### **Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants**

Block, S. L., Klein, N. P., Sarpong, K., Russell, S., Fling, J., Petrecz, M., Flores, S., Xu, J., Liu, G., Stek, J. E., Foglia, G. & Lee, A. W., 2017, In : Pediatric Infectious Disease Journal. 36, 2, p. 202-208 7 p.

### **Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age**

Gorse, G. J., Falsey, A. R., Fling, J. A., Poling, T. L., Strout, C. B. & Tsang, P. H., 1 May 2013, In : Vaccine. 31, 19, p. 2358-2365 8 p.

### **Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis**

Spraker, M. K., Gisoldi, E. M., Siegfried, E. C., Fling, J. A., De Espinosa, Z. D., Quiring, J. N. & Zangrilli, S. G., 1 Feb 2006, In : Cutis. 77, 2, p. 113-120 8 p.

### **Exercise-induced airflow obstruction in a healthy military population**

O'Donnell, A. E. & Fling, J., 1993, In : Chest. 103, 3, p. 742-744 3 p.

### **Two rapid methods for determination of serum theophylline concentrations: A comparison**

Fling, J. A., Widish, J. R., Heald, J. I., Olsen, P. E., Reid, M. J. & Martin, M. E., 1 Jan 1989, In : Annals of Allergy. 62, 1, p. 35-37 3 p.

### **Suppression of the late cutaneous response by immunotherapy**

Fling, J. A., Ruff, M. E., Parker, W. A., Whisman, B. A., Martin, M. E., Moss, R. B. & Reid, M. J., Jan 1989, In : The Journal of Allergy and Clinical Immunology. 83, 1, p. 101-109 9 p.

**The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: A cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force**

Fling, J. A., Fischer, J. R., Boswell, R. N. & Reid, M. J., Dec 1988, In : The Journal of Allergy and Clinical Immunology. 82, 6, p. 965-970 6 p.

**Epidemiology of emergency room asthma in northern California: Association with IgE antibody to ryegrass pollen**

Pollart, S. M., Reid, M. J., Fling, J. A., Chapman, M. D. & Platts-Mills, T. A. E., Aug 1988, In : The Journal of Allergy and Clinical Immunology. 82, 2, p. 224-230 7 p.

## **Sponsored Projects**

**A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants**

Fling, J.

MedImmune, LLC

8/11/16 → 7/11/21

**A PHASE 3, PLACEBO CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER**

Fling, J.

Pfizer, Inc.

13/04/17 → 13/04/21

**A Phase IIIA, Blinded, Randomized, Controlled. Multinational, Consistency Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' MMR Vaccine,(209762) Compared to Merck & Co., Inc.'s MMR Vaccine as a First**

Fling, J.

GlaxoSmithKline

8/10/13 → 31/10/18

**A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study-Assess Safety/Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine-Administered Concomitantly with Routine Vaccines to Healthy Infants.**

Fling, J.

GlaxoSmithKline

6/01/19 → 5/06/23

**A Phase III, Randomised, Multicenter Study, Double-Blind for the Immunogenicity and Consistency Evaluation of 3 Lots of GSK Biologicals' Haemophilus Influenzae Type b (Hib) Conjugate Vaccine and Single-Blind and Controlled for the Evaluation of Safety an**

Fling, J. & Habiba, N.

GlaxoSmithKline

22/02/10 → 15/01/13

**A Phase III Randomized, Partially Double-Blind, Active-Comparator Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Health Infants When Given at 2,4, and 6 Months Concomitantly with P**

Fling, J. & Habiba, N.

Merck Co.

1/07/11 → 22/05/15

**A Phase III Stratified, Remdomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immumogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-adjuvanted Comparator**

Fling, J.

Novartis Pharmaceuticals

28/10/14 → 31/10/19

**A Phase IV, Open-Label Administration (The Trial Statistician and Laboratory Technicians will be Blinded to Group Assignment), Randomized (Group 1 and 2), Parallel-Group, Multicenter Trial to Evaluate the Immunogenicity and Safety of 2 Doses of**

Fling, J.  
Sanofi Pasteur, Inc.  
3/08/12 → 31/08/15

**A Phase Stratified, Randomized, Double-blind, Multicenter, Non-inferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus in Subjects Ages**

Fling, J.  
Novartis Pharmaceuticals  
30/10/13 → 31/10/18

**A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children**

Fling, J.  
MedImmune, LLC  
8/03/10 → 31/03/11

**Efficacy Study of Fluzone High-dose Vaccine Compared with Fluzone Vaccine in Elderly Adults**

Fling, J.  
Sanofi Pasteur, Inc.  
29/07/11 → 31/07/14

**Efficacy Study of Fluzone High-dose Vaccine Compared with Fluzone Vaccine in Elderly Adults**

Fling, J.  
Sanofi Pasteur, Inc.  
1/10/12 → 31/10/15

**"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years"**

Fling, J.  
Sanofi Pasteur, Inc.  
10/06/16 → 10/06/21

**Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers**

Fling, J.  
Sanofi Pasteur, Inc.  
16/08/18 → 31/12/19

**Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years**

Fling, J.  
Sanofi Pasteur, Inc.  
12/10/12 → 31/10/15

**Immunogenicity, reactogenicity and safety study of Pediarix, Hiberix and Prevenar 13 co-administered with two different formulations of GSK Biologicals' HRV vaccine (444563) in healthy infants 6-12 weeks of age.**

Fling, J.  
GlaxoSmithKline  
7/07/17 → 6/07/21

**Phase III, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and a US-licensed QIV in Healthy Subjects aged 6 Months through 47 Months**

Fling, J.  
Syneos Health  
1/08/19 → 31/12/20

**Phase IV Multi-Year Efficacy Study of Fluzone High-Dose Trivalent Vaccine Compared With Fluzone Vaccine In Adults 65 Years of Age or Older**

Fling, J.  
Sanofi Pasteur, Inc.  
17/09/09 → 31/08/10

**Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine**

Fling, J. & Habiba, N.  
Sanofi Pasteur, Inc.  
9/11/10 → 9/11/11

**Safety and Immunogenicity of Fluzone Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age**

Fling, J.  
Sanofi Pasteur, Inc.  
5/08/16 → 4/08/21

**Safety and Immunogenicity of Revaccination with Influenza Vaccine in Healthy Adult Subjects aged 18 to 64 Years who were Previously Vaccinated with Fluzone ID or Fluzone IM**

Fling, J.  
Sanofi Pasteur, Inc.  
11/09/09 → 31/08/10